Differential cardioprotection with selective inhibitors of adenosine metabolism and transport: Role of purine release in ischemic and reperfusion injury

Molecular and Cellular Biochemistry

Volumn 180, Issue 1-2, 1998, Pages 179-191

  Abd Elfattah, Anwar S ^a   Jessen, Michael E ^a   Lekven, Jon ^a   Wechsler, Andrew S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenine nucleotides and nucleosides; Adenosine and inosine; Free radicals mediated injury; Ischemic and reperfusion injury; Myocardial stunning; Nucleoside transport; Ventricular arrhythmias; Ventricular function

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ADENINE NUCLEOTIDE; ADENOSINE; ADENOSINE TRIPHOSPHATE; INOSINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITROBENZYLTHIOINOSINE; NUCLEOSIDE; PURINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG HALF LIFE; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE REPERFUSION; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; NUCLEIC ACID METABOLISM; NUCLEOSIDE TRANSPORT; REPERFUSION INJURY; STUNNED HEART MUSCLE;

ADENINE; ADENOSINE; ADENOSINE DEAMINASE; ANIMALS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; DOGS; ENZYME INHIBITORS; MEMBRANE PROTEINS; MODELS, CARDIOVASCULAR; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NUCLEOSIDE TRANSPORT PROTEINS; PURINES; THIOINOSINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0031934262     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006828115191     Document Type: Article

References (68)

1. Abd-Elfattah AS, Wechsler AS: (eds). In: Purines and Myocardial Protection. Kluwer Academic Publishers, 1996
2. Abd-Elfattah AS, Wechsler AS: Myocardial protection in cardiac surgery: Subcellular basis for myocardial injury and protection. Adv Cardiac Surg 3: 73-112, 1991
3. Belardinelli L, Pelleg A: Adenosine and adenine nucleotides: From molecular biology to integrative physiology. Kluwer Academic Publishers, 1995
4. Lerman BB, Berlardineli L: Cardiac electrophysiology of adenosine: Basic and clinical concepts. Circulation 83: 1499-1509, 1991
5. Foker JE, Einzig S, Wang T: Adenosine metabolism and myocardial preservation: Consequences of adenosine catabolism on myocardial high-energy compounds and tissue blood flow. J Thorac Cardiovasc Surg 80: 506-516, 1980
6. Ely SW, Mentzer RM, Lasley RD, Lee BK, Berne RM: Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg 90: 549-556, 1990
7. de Jong WJ, van der Meer P, van Loon H, Owen P, Opie LH: Adenosine as adjunct to potassium cardioplegia: Effect on function, energy metabolism, and electrophysiology. J Thorac Cardiovasc Surg 100: 445-454, 1990
8. Babbitt OG, Virmani R, Vildibill HD, Norton ED, Forman M: Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: Effect on infarct size, ventricular function, and regional myocardial blood flow. Am Heart J 120: 808-818, 1990
9. Sollevi A: Clinical studies on the effect of adenosine in role of adenosine and adenine nucleotides in the biological system. In: S Imai, M Nakazawa, (eds). Elsevier Science Publishers, Amsterdam, New York, 1991, pp 525-537
10. Huizer T, de Jong JW, Nelson JA, Czarnecki W, Serruys PW, Bonnier JJRM, Toquay R: Urate production by human heart. J Mol Cell Cardiol 21: 691-695, 1989
11. Edlund A, Straat E, Henricksson P: Infusion of adenosine provokes myocardial ischemia in patients with ischemic heart disease. Clin Physiol 9: 309-313, 1989
12. Sylven C, Jonzon B, Fredholm BB, Kaijser L: Adenosine injection into the brachial artery produces ischemia like pain or discomfort in the forearm. Cardiovasc Res 22: 674-678, 1988
13. Crea F, El-Tamimi H, Veijar M, Kaski JC, Davies G, Maseri A: Adenosine-induced chest pain in patients with silent and painful myocardial ischemia: Another clue to the importance of generalized defective perception of painful stimuli as a cause of silent ischemia. Eur Heart J 9(suppl N): 34-39, 1988
14. Ceccareli M, Ciompi ML, Pasero G: Acute renal failure during adenine therapy in the lesch-nyhan syndrome. In: P Sperling, AS De Vries, JB Wyugaarden (eds). Purine Metabolism in Man. Raven Press, New York, 1974, pp 671-679
15. Ramos-Salazar A, Baines AD: Role of 5′-nucleotidase in adenosine-mediated renal vasoconstriction during hypoxia. J Pharmacol Exp Ther 230: 494-499, 1986
16. Abd-Elfattah AS, Jessen ME, Lekven J, Doherty NE III, Brunsting LA, Wechsler AS: Myocardial reperfusion injury: Role of myocardial hypoxanthine and xanthine on 'free-radical mediated reperfusion injury.' Circulation 1988; 78(suppl III): 224-235
17. Abd-Elfattah AS, Jessen ME, Hanan SA, Tuchy G, Wechsler AS: Is adenosine-5′-triphosphate derangement or free-radical-mediated injury the major cause of ventricular dysfunction during reperfusion? Role of adenine nucleoside transport in myocardial reperfusion injury. Circulation; 82(suppl IV): IV-341-350, 1990
18. Abd-Elfattah AS, Ding M, Wechsler AS: Protection of the stunned myocardium: Selective nucleoside transport blocker (NBMPR) administered after 20 min of ischemia augments recovery of ventricular function. Circulation; 88 [part 2]: 336-343, 1993
19. Abd-Elfattah AS, Jessen ME, Wechsler AS: Nucleoside Trapping during reperfusion prevents ventricular dysfunction 'stunning' in absence of adenosine: Possible separation between ischemic and reperfusion injury. J Thorac Cardiovasc Surg 108: 269-278, 1994
20. Abd-Elfattah AS, Wechsler AS: Separation between ischemic and reperfusion injury by site specific entrapment of endogenous adenosine and inosine using NBMPR and EHNA. J Cardiac Surgery 9 (suppl): 387-396, 1994
21. Abd-ElfattahASA, Wechsler AS: Nucleoside transport and myocardial injury and protection: Possible separation between ischemic and reperfusion injury by selective nucleoside transport blocker NBMPR. In: AS Abd-Elfattah, AS Wechsler (eds). Purines and Myocardial Protection. Kluwer Academic Publishers, 1995
22. Abd-Elfattah AS, Ding M, Wechsler AS: Intermittent warm aortic cross-clamping prevents cumulative ATP depletion, ventricular fbrillation and dysfunction 'stunning': Is it preconditioning? J Thorac Cardiovasc Surg 110: 328-339, 1995
23. Abd-Elfattah ASA, Maddox R, Jessen ME, Hanan SA, Wechsler AS: Selective nucleoside transport blocker NBMPR attenuates myocardial stunning in a rabbit model-defcient of xanthine oxidase. In: AS Abd-Elfattah, AS Wechsler (eds). Purines and Myocardial Protection, Kluwer Academic Publishers, 1995
24. Dow JW: Metabolism of purines by adult cardiomyocytes. In: HM Piper, G Isenberg, (eds). Isolated adult cardiomyocytes. 1989, pp 216-237
25. Jennings RB, Reimer KA, Hill ML, et al.: Total ischemia, in dogs hearts, in vitro. I. Comparison of high energy phosphate production, utilization and depletion and adenine nucleotide catabolism in total ischemia in vitro vs. severe ischemia in vivo. Circ Res 49: 892-900, 1981
26. Jarasch ED, Bruder G, Heid HW: Significance of xanthine oxidase in capillary endothelial cells. Acta Physiol Scand 548(suppl): 39-46, 1986
27. Chambers DE, Parks DA, Patterson G, et al.: Xanthine oxidase as a source of free radical damage in myocardial ischemia. J Mol Cell Cardiol 17: 145-152, 1985
28. Eddy LJ, Stewart JR, Jones HP, Engerson TD, McCord JM, Downey JM: Free radical producing enzyme, xanthine oxidase is undetectable in human hearts. Am J Physiol 253: H709-H711, 1987
29. Muxfeldt M, Schaper W: The activity of xanthine oxidase in hearts of pigs, guinea pigs, rats and humans. Basic Res Cardiol 82: 486-492, 1987
30. Abd-Elfattah AS, Salter DR, Murphy CE, Goldstein JP, Brunsting LA, Wechsler AS: Metabolic differences between retrograde and antegrade cardioplegia after reversible normothermic global ischemic injury. Surg Forum 37: 267-270, 1986
31. Bolli R. Oxygen-derived free eadiacals and myocardial reperfusion injury. An overview. Cardiovasc Drug Ther 5: 225-236, 1991
32. Zwier JL. Measurement of superoxide-derived free radicals inthe reperfused heart: Evidence for a free radical mechanism of reperfusion injury. J Biol Chem 263: 1353-1357, 1988
33. Horwitz LD, Fennessey PV, Shikesss RH, Kong Y. Marked reduction in myocardial infarct size due to prolonged infusion of an antioxidant during reperfusion. Circulation 89: 1792-1801, 1994
34. Akizuki S, Yoshida, Chamber DE, Eddy LJ, Paaarmley LF, Yellon DM, Downey JM. Infarct size limitation by the xanthine oxidase inhibitor allopurinol, in closed chest dogs with small infarcts. Cardiovasc Res 19: 686-692, 1985
35. Glower DD, Spratt JA, Snow ND, Kabas JS, Davis JW, Olsen CO, Tyson GS, Sabiston DC, Rankin JS: Linearity of the Frank-Starling relationship in the intact heart: The concept of preload recruitable stroke work. Circulation 71: 994-1009, 1985
36. Spratt JA, Tyson GS, Glower DD, Davis JW, Muhlbair LH, Olsen CO, Rankin JS: The end systolic pressure-volume relationship in conscious dogs. Circulation 75: 1295-1309, 1987
37. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with Folin phenol reagent. J Biol Chem 193: 265-275, 1951
38. Abd-Elfattah AS, Wechsler AS: Superiority of HPLC to assay for enzymes regulating adenine nucleotidase pool intermediates metabolism: 5′-nucleotidase, adenylate deaminase, adenosine deaminase and adenylosuccinate lyase: A simple and rapid determination of adenosine. J Liquid Chromatogr 10: 2653-2694, 1987
39. Lamb CU, Nelson DJ: Pharmacokinetics of inhibition of adenosine deaminase by erythro-9 (2-hyroxy-3-nonyl) adenine in CBA mice. Biochem Pharmacol 31: 535-539, 1982
40. Van der Hied R, Reimer KA, Jennings RB: Adenosine slow ischemic metabolism in canine myocardium in vitro: Relationship to ischemic preonditioning. Cardiovasc Res 27: 669-673, 1993
41. Abd-Elfattah ASA, Quo JH, El-Quessaab E, Goa SP, Mahgoub M: Failure of adenosine deaminase inhibitors (+)EHNA, PVP-27, PVP-30 and VMV to favorably accumnalte adenosine and protect against myocardial ischemia. J Mol Cell Cardiol; 28: (abstr) A182, 1996
42. Vargeese C, Sarma MSP, Pragacharyulu PVP et al.: Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolises of (+)-erythro-9-(2S-hydroxy-3R nonyl)adenine. J Med Chem 37: 3844-3849, 1994
43. Van Wylen DGL, Willis J, Sodhi J, Weiss RJ, Lasley RD, Mentzer RM Jr: Cardiac microdialysis to estimate regional interstitial adenosine concentration and coronary blood flow. Am J Physiol 258: H1642-H1649, 1990
44. Van-Wylen DGL: Assessment of interstitial fluid adenosine: Implication for exogenous and endogenous adenosine-mediated cardioprotection. In: AS Abd-Elfattah, AS Wechsler (eds). Purines and Myocardial Protection. Kluwer Academic Publishers, 1996, pp 81-94
45. Wang T, Mentzer RM Jr, Van Wylen DG: Interstitial adenosine with dipyridamole: Effect of adenosine receptor blockade and adenosine deaminase inhibition. Am J Physiol 263: H552-H558, 1992
46. Tibi PR, Patti CS, Pearce FJ, Hicks GL: Deleterious effects of dipyridamole during reperfusion of ischemic myocardium. Surgery 36: 255-258, 1985
47. Takeo S, Tanonaka K, Tazuma Y, Fukao N, Yoshikawa C, Fukumoto T, Tanaka T: Diltiazem and verapamil reduce the loss of adenine nucleotide metabolites from hypoxic hearts. J Mol Cell Cardiol 1988: 20(5): 443-456, 1988
48. Lesnefsky EJ, Van Benthuysen KM, McMurtry IF, Shikes RH, Johnston RB Jr, Horwitz LD: Lidocaine reduces canine infarct size and decreases release of a lipid peroxidation product. J Cardiovasc Pharmacol 13: 895-901, 1989
49. Flameng W, Dacnen W, gorgers M, Thone F, Xhonneux R, van de Waters A, Van Belle H: Cardioprotective effects of lidoflazine during lh of normothermic global ischemia. Circulation 64: 796-807, 1981
50. Gruber HE, Hoffer MF, McAllister DR, Laikind PK, Lame TA, Schmid-Schoenbin GW, Engler RL: Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: Effects on flow, granulocytes and injury. Circulation 80: 1400-1411, 1989
51. 2+
52. Flameng W, Xhonneux R, Van Belle H, van de Waters A, Wouters L, Wijoants J, Thone' F, Van Deale P, Janssen PA: Cardioprotective effects of mioflazine during 1h normothermic global ischemia in the canine heart. Cardiovasc Res 18: 528-537, 1984
53. Gorgers M, et al. : Pathophysiology of cardiomyocytes. Ann NY Acad Sci 5: 433-453, 1988
54. Buchwald A, Ito BR, Schaper W: Influence of mioflazine on canine coronary blood flow and on adenine nucleotide and nucleoside content under normal and ischemic conditions. J Cardiovasc Pharmacol 10: 213-221, 1987
55. Paterson ARP, Jakobs ES, Ng CYC, Odegard RD, Adjoi AA: Nucleoside transport inhibition in vitro and in vivo. In: E Gerlach, BF Becker (eds). Topics and Perspectives in Adenosine Research. Springer-Verlag, Berlin, 1987, pp 89-101
56. Zughaib ME, Abd-Elfattah AS, Jeroudi MO, Sun J-Z, Sekili S, Tang X-L, Bolli R: Inhibitors of adenosine deaminase and nucleoside transport attenuate myocardial 'stunning' independently of coronary flow or hemodynamic effects. Circulation 88 [part 1]: 2359-2369, 1993
57. Hearse DJ, Garlick PB, Humphrey SP: Ischemia contracture of the myocardium: Mechanisms and prevention. Am J Cardiol 39: 986-993, 1977
58. Glower DD, Spratt JA, Newton JR, Wolf JA, Rankin JS, Swain JL: Dissociation between early recovery of regional function and purine nucleotidase content in postischemic myocardium in conscious dogs. Cardiovasc Res 21: 328-336, 1987
59. Hearse DJ: Oxygen derivation and early myocardial contractile failure: A reassessment of the role of adenosine triphosphate. Am J Cardiol 44: 1115-1121, 1979
60. Gram CM, Ketai LH, Myers CL, Shlafer M: Purine efflux after cardiac ischemia: Relevance to allopurinol cardioprotection. Am J Physiol 252: H368-H373, 1987
61. Fox AC, Reed GE, Meilman H, Silk BB: Release of nucleoside from canine and human hearts as an index of prior ischemia. Am J Cardiol 43: 52-58, 1979
62. 1-adenosine receptors. Am J Physiol 257: H1952-H1957, 1989
63. Lasley RD, Mentzer RM: Adenosine improves recovery of post-ischemic myocardial function via an adenosine A, receptor mechanism. Am J Physiol 263: H1460-H1465, 1992
64. 1 adenosine receptors in rabbit heart. Circulation 84: 350-356, 1991
65. Cave AC, Downey JM, Hearse DJ: Adenosine fails to substitute for preconditioning in the globally ischemic isolated rat heart. J Mol Cell Cardiol 1991; 23: (abst) P-3-30
66. 1 receptor activation. Circulation 1992; 86(spl I: I-342, (abstr) 1992
67. Abd-Elfattah AS, Ding M, Wechsler AS: Myocardial stunning and preconditioning: Age-, species-, and model-related differences: Role of AMP-5′-nucleotidase in myocardial injury and protection. J Cardiac Surg 199(35): 101-105
68. 1-receptor blockade augments postischemic ventricular dysfunction 'stunning' in the presence or absence of endogenous adenosine. Circulation (suppl I); 88: 1-131, (abstr) 1993